FIELD: chemistry.
SUBSTANCE: invention represents method of obtaining preparation, which contains amorphous or amorphous-crystalline salts of orotic acid, which includes thermal processing of crystalline potassium orotate and/or magnesium orotate with the following milling in milling activating device; thermal processing constitutes in thermostatting at temperature 115-125°C for 40-60 min, and as milling activating device ball epicyclical miller is applied; milling is carried out for the time, necessary for supply of specific energy 7-10 kJ/g.
EFFECT: creation of preparations based on of orotic acid salts, characterised by increased solubility, rate of solution and biological availability.
6 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MECHANO-ACTIVATED AMORPHOUS AND AMORPHOUS-CRYSTALLINE CALCIUM SALTS OF GLUCONIC ACID, COMPOSITIONS, METHODS OF PRODUCTION, PHARMACEUTICAL PREPARATIONS AND METHOD OF TREATMENT BASED ON SAID PREPARATIONS | 2007 |
|
RU2373185C2 |
| DIPROPIONATE BETULIN COMPOSITION | 2013 |
|
RU2541153C1 |
| BETULIN DIACETATE-BASED COMPOSITION | 2013 |
|
RU2517157C1 |
| ALISKIREN AND OROTIC ACID SALT | 2007 |
|
RU2456267C2 |
| PHARMACOLOGICAL COMPOSITION FOR INCREASING BODY ADAPTABILITY UNDER EXERCISE CONDITIONS | 2014 |
|
RU2564949C1 |
| NOVEL COMPOSITIONS AND METHODS OF PRODUCING 5-AMINO- OR SUBSTITUTED AMINO-1,2,3-TRIAZOLES AND TRIAZOLE-OROTATE COMPOSITIONS | 2010 |
|
RU2594155C2 |
| ADDUCTS OF OROTIC ACID WITH AMINO ACIDS OR AMINES SHOWING HEPATOPROTECTIVE EFFECT | 1993 |
|
RU2047606C1 |
| METHOD FOR OBTAINING AMORPHOUS WATER-SOLUBLE SALTS OF MAGNESIUM CITRATE | 2020 |
|
RU2756322C1 |
| 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE OROTATE DIHYDRATE AND METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2690674C2 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTI-ANGINAL, ANTI-ISCHEMIC AND NOOTROPIC EFFECT | 2003 |
|
RU2225713C1 |
